Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation.

Journal of neuroimmunology - 30 Mar 2010

Esposito Marianna, Ruffini Francesca, Bellone Matteo, Gagliani Nicola, Battaglia Manuela, Martino Gianvito, Furlan Roberto

Abstract excerpt

Rapamycin is an oral immunosuppressant drug previously reported to efficiently induce naturally occurring CD4(+)CD25(+)FoxP3(+) regulatory T ((n)T(reg)) cells re-establishing long-term immune self-tolerance in autoimmune diseases. We investigated the effect of rapamycin administration to SJL/j mi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Differentiation, T-Lymphocyte
Share to Encephalomyelitis, Autoimmune, Experimental

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Tolerance

Share to Interleukin-17

Share to Multiple Sclerosis, Relapsing-Remitting

Share to Myelin Proteolipid Protein

Share to Secondary Prevention

Share to Sirolimus

Source

Identifiers

PMID: 20149931
DOI: 10.1016/j.jneuroim.2010.01.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20149931-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation.PMID 20149931Read ↗

Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin.Semantic proximity Read ↗

Treatment with rapamycin can restore regulatory T-cell function in IPEX patients.Semantic proximity Read ↗

Rapamycin enriches for CD4+ CD25+ CD27+ Foxp3+ regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosisSemantic proximity Read ↗

Rapamycin and abundant TCR stimulation are required for the generation of stable human induced regulatory T cellsSemantic proximity Read ↗

Long-term rapamycin treatment suppresses IL-17-producing gamma delta T cells and blunts neuroinflammation in agingSemantic proximity Read ↗

Rapamycin rescues loss-of-function in blood-brain barrier-interacting regulatory T cellsSemantic proximity Read ↗

Effect of in vivo rapamycin treatment on de novo T-cell development in relation to induction of autoimmune-like immunopathology in the rat.Semantic proximity Read ↗

Regulatory T Cell Stability and Migration Are Dependent on mTOR.Semantic proximity Read ↗

Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells.Semantic proximity Read ↗

Rapamycin Ameliorates Dystrophic Phenotype in mdx Mouse Skeletal MuscleSemantic proximity Read ↗

Rapamycin prevents bronchiolitis obliterans through increasing infiltration of regulatory B cells in a murine tracheal transplantation model.Semantic proximity Read ↗

Ex vivo expanded regulatory T cells CD4+CD25+FoxP3+CD127Low develop strong immunosuppressive activity in patients with remitting-relapsing multiple sclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.